Medera Presents Late-Breaking Clinical Trial Data at ESC Congress 2026 Demonstrating Durable Improvement in HFpEF Cardiac Filling Pressures Following SRD-002 Gene Therapy

Medera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial showing that 80% of patients met the prespecified threshold for normalization of cardiac filling pressures, with approximately 30% reduction in peak exercise pulmonary capillary wedge pressure. The trial demonstrated a favorable safety profile with no treatment-related serious adverse events across all 10 treated patients. Results support advancement to a randomized Phase 2b trial for SRD-002, a single-dose intracoronary AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction.